Clearmind Medicine Yönetim

Yönetim kriter kontrolleri 1/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Adi Zuloff-Shani

İcra Kurulu Başkanı

US$336.3k

Toplam tazminat

CEO maaş yüzdesi	41.7%
CEO görev süresi	2.7yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Nov 10

CEO Tazminat Analizi

Adi Zuloff-Shani'un ücretlendirmesi Clearmind Medicine'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Oct 31 2023	n/a	n/a	-US$9m
Jul 31 2023	n/a	n/a	-US$6m
Apr 30 2023	n/a	n/a	-US$7m
Jan 31 2023	n/a	n/a	-US$7m
Oct 31 2022	n/a	n/a	-US$7m
Jul 31 2022	n/a	n/a	-US$7m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	-US$4m
Oct 31 2021	US$145k	US$113k	-US$3m

Tazminat ve Piyasa: Adi's total compensation ($USD336.34K) is above average for companies of similar size in the Canadian market ($USD177.18K).

Tazminat ve Kazançlar: Insufficient data to compare Adi's compensation with company performance.

CEO

Adi Zuloff-Shani (54 yo)

2.7yrs

Görev süresi

Dr. Adi Zuloff-Shani, Ph D., serves as Member of Scientific Advisory Board at Save Foods, Inc. since October 2021. She serves as Chief Executive Officer of Clearmind Medicine Inc., since July 14, 2021.She...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adi Zuloff-Shani	Chief Executive Officer	2.7yrs	Veri yok	Veri yok
Alan Rootenberg	Chief Financial Officer	1.8yrs	Veri yok	0% CA$ 0
Mark Haden	Vice President of Business Development	2.7yrs	Veri yok	0% CA$ 0
Gilad Babchuk	Head of Strategy & Communication	2.2yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim: CMND's management team is considered experienced (2.4 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Haden	Vice President of Business Development	2.6yrs	Veri yok	0% CA$ 0
John Krystal	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Michael Davidson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Alon Friedman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Wim van den Brink	Member of Scientific Advisory Board	2.4yrs	Veri yok	Veri yok
Oz Adler	Independent Director	2.3yrs	Veri yok	0.0036% CA$ 184.1
Amitai Weiss	Independent Chairman	4.6yrs	Veri yok	0% CA$ 0
Yehonatan Shachar	Independent Director	3.9yrs	Veri yok	0% CA$ 0
Gabriele Fischer	Member of Scientific Advisory Board	2.4yrs	Veri yok	Veri yok
Gal Yadid	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Christian Schutz	Member of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Asaf Itzhaik	Director	1.3yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CMND's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Clearmind Medicine Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Inc. Announces Board Appointments

High number of new and inexperienced directors

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board

Recent updates

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

High number of new and inexperienced directors

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction Treatment

Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board

Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as Director

Clearmind Medicine Inc. Announces CFO Changes

Clearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Clearmind Medicine Inc. and Scisparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption

SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory Board

Less than half of directors are independent

Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd.

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Clearmind Medicine Inc. announced that it has received CAD 6.225 million in funding

Clearmind Medicine Inc. announced that it expects to receive CAD 6 million in funding

CEO Tazminat Analizi

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş